Theravance Biopharma (NASDAQ:TBPH) Downgraded by Zacks Research to “Hold”

Theravance Biopharma (NASDAQ:TBPH) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Monday, Zacks reports.

Several other equities analysts have also issued reports on the stock. BTIG Research lowered shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Monday, June 29th. JonesTrading downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Monday, June 29th. Wall Street Zen lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. HC Wainwright cut Theravance Biopharma from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $15.00 to $17.00 in a research note on Tuesday, July 7th. Finally, Weiss Ratings raised Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, August 17th. Eight research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Theravance Biopharma currently has a consensus rating of “Hold” and a consensus price target of $19.40.

Theravance Biopharma Stock Performance

TBPH stock opened at $17.06 on Monday. Theravance Biopharma has a fifty-two week low of $13.08 and a fifty-two week high of $21.03. The company has a market capitalization of $885.76 million, a price-to-earnings ratio of 16.89 and a beta of 0.25. The business’s 50 day moving average price is $16.95 and its two-hundred day moving average price is $16.49.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.18). The firm had revenue of $20.73 million during the quarter, compared to analysts’ expectations of $22.49 million. Theravance Biopharma had a negative return on equity of 0.77% and a net margin of 51.58%. Sell-side analysts forecast that Theravance Biopharma will post 1.56 earnings per share for the current year.

Insiders Place Their Bets

In related news, major shareholder Eli Samaha sold 37,799 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $17.00, for a total value of $642,583.00. Following the transaction, the insider owned 9,174,453 shares of the company’s stock, valued at approximately $155,965,701. This trade represents a 0.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Rhonda Farnum sold 13,314 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $16.39, for a total transaction of $218,216.46. Following the completion of the transaction, the senior vice president directly owned 232,457 shares in the company, valued at approximately $3,809,970.23. The trade was a 5.42% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 350,011 shares of company stock valued at $6,008,309. 7.65% of the stock is owned by company insiders.

Institutional Investors Weigh In On Theravance Biopharma

Hedge funds have recently modified their holdings of the business. Arrowstreet Capital Limited Partnership bought a new stake in Theravance Biopharma during the third quarter valued at about $10,611,000. California State Teachers Retirement System increased its stake in shares of Theravance Biopharma by 1,550.9% in the second quarter. California State Teachers Retirement System now owns 672,911 shares of the biopharmaceutical company’s stock worth $11,439,000 after purchasing an additional 632,150 shares in the last quarter. Pacer Advisors Inc. bought a new stake in shares of Theravance Biopharma during the 4th quarter valued at $6,342,000. Janus Henderson Group PLC lifted its stake in shares of Theravance Biopharma by 214.8% during the 4th quarter. Janus Henderson Group PLC now owns 400,496 shares of the biopharmaceutical company’s stock valued at $7,493,000 after buying an additional 273,288 shares in the last quarter. Finally, Two Sigma Investments LP boosted its holdings in Theravance Biopharma by 1,199.9% in the 3rd quarter. Two Sigma Investments LP now owns 231,272 shares of the biopharmaceutical company’s stock worth $3,377,000 after buying an additional 213,480 shares during the period. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.